Multisystem immune-related adverse reactions with immune checkpoint inhibitors

被引：0

作者：

Jayson, Amy ^{[1
]}

Tsambarlis, Maria ^{[1
]}

Thakkar, Hardik ^{[1
]}

Ludlow, Steven P. ^{[1
]}

Syed, Misbahuddin ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2025年 / 38卷 / 06期

关键词：

immune checkpoint inhibitors; immune-related adverse reactions; nivolumab; ipilimumab; oncology; dermatitis; EVENTS;

D O I：

10.1097/01.JAA.0000000000000211

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors have transformed oncologic practice, producing durable responses in many patients with advanced malignancies. However, these treatments can cause immune-related adverse reactions. This article describes a patient with metastatic non-small cell lung cancer who developed toxicities involving multiple organ systems shortly after receiving combined ipilimumab and nivolumab. Although toxicity is more common in just one organ system, multisystem adverse reactions are possible, and clinicians who recognize and manage these reactions promptly can improve patient outcomes.

引用

页码：29 / 31

页数：3

共 11 条

[1] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J].

Bagchi, Sreya ;

Yuan, Robert ;

Engleman, Edgar G. .

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 :223-249

[2] Original Research Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy [J].

Ghisoni, E. ;

Wicky, A. ;

Bouchaab, H. ;

Imbimbo, M. ;

Delyon, J. ;

Moura, B. Gautron ;

Gerard, C. L. ;

Latifyan, S. ;

Ozdemir, B. C. ;

Caikovski, M. ;

Pradervand, S. ;

Tavazzi, E. ;

Gatta, R. ;

Marandino, L. ;

Valabrega, G. ;

Aglietta, M. ;

Obeid, M. ;

Homicsko, K. ;

Alfonso, N. N. Mederos ;

Zimmermann, S. ;

Coukos, G. ;

Peters, S. ;

Cuendet, M. A. ;

Di Maio, M. ;

Michielin, O. .

EUROPEAN JOURNAL OF CANCER, 2021, 149 :153-164

[3] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

[4] Immune-checkpoint inhibitors: long-term implications of toxicity [J].

Johnson, Douglas B. ;

Nebhan, Caroline A. ;

Moslehi, Javid J. ;

Balko, Justin M. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (04) :254-267

[5] Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab [J].

Kichenadasse, Ganessan ;

Miners, John O. ;

Mangoni, Arduino A. ;

Rowland, Andrew ;

Hopkins, Ashley M. ;

Sorich, Michael J. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (09) :1191-1199

[6]

National Comprehensive Cancer Network, 2025, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer: National Comprehensive Cancer Network

[7]

Remolina-Bonilla YA, 2020, ONCOLOGY-NY, V34, P171

[8] Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer [J].

Shankar, Bairavi ;

Zhang, Jiajia ;

Naqash, Abdul Rafeh ;

Forde, Patrick M. ;

Feliciano, Josephine L. ;

Marrone, Kristen A. ;

Ettinger, David S. ;

Hann, Christine L. ;

Brahmer, Julie R. ;

Ricciuti, Biagio ;

Owen, Dwight ;

Toi, Yukihiro ;

Walker, Paul ;

Otterson, Gregory A. ;

Patel, Sandip H. ;

Sugawara, Shunichi ;

Naidoo, Jarushka .

JAMA ONCOLOGY, 2020, 6 (12) :1952-1956

[9] Regulatory circuits of T cell function in cancer [J].

Speiser, Daniel E. ;

Ho, Ping-Chih ;

Verdeil, Gregory .

NATURE REVIEWS IMMUNOLOGY, 2016, 16 (10) :500-611

[10] Systemic Immunity Is Required for Effective Cancer Immunotherapy [J].

Spitzer, Matthew H. ;

Carmi, Yaron ;

Reticker-Flynn, Nathan E. ;

Kwek, Serena S. ;

Madhireddy, Deepthi ;

Martins, Maria M. ;

Gherardini, Pier Federico ;

Prestwood, Tyler R. ;

Chabon, Jonathan ;

Bendall, Sean C. ;

Fong, Lawrence ;

Nolan, Garry P. ;

Engleman, Edgar G. .

CELL, 2017, 168 (03) :487-+

← 1 2 →